Literature DB >> 1479389

Anticoagulant treatment as a risk factor for primary intracerebral haemorrhage.

R Fogelholm1, K Eskola, T Kiminkinen, I Kunnamo.   

Abstract

Forty one (14.2%) of 288 patients with primary intracerebral haemorrhage occurring between September 1985 and December 1989 in Central Finland were on anticoagulant treatment at the onset of symptoms. In a sample of 29,000 subjects from the same population the prevalence of anticoagulant treatment was 1.6% in those aged 40 years or older. The estimated age adjusted odds ratio of being on anticoagulant treatment at the time of primary intracerebral haemorrhage was 6.7 (95% CI from 4.5 to 9.9). The risk was highest during the first year of anticoagulation. Overtreatment (thrombotest value < 5%) was slightly more common among the patients. The haematoma volumes measured from the CT scans were similar in patients on anticoagulant treatment and those not anticoagulated. The case fatality rate during the first week and the mortality during follow up of 32 months were slightly higher, and the functional outcome slightly worse in the anticoagulated group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479389      PMCID: PMC1015323          DOI: 10.1136/jnnp.55.12.1121

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

2.  Intensity of anticoagulant treatment and risk of intracerebral hematoma.

Authors:  G W Albers
Journal:  Stroke       Date:  1990-12       Impact factor: 7.914

3.  Primary intracerebral haemorrhage in the Jyväskylä region, central Finland, 1985-89: incidence, case fatality rate, and functional outcome.

Authors:  R Fogelholm; M Nuutila; A L Vuorela
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-07       Impact factor: 10.154

4.  Cerebral haemorrhage and anticoagulants.

Authors:  H P Mattle
Journal:  Ir Med J       Date:  1990-06

5.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.

Authors:  C S Landefeld; L Goldman
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

Review 6.  Anticoagulant drugs in the elderly: valuable in selected patients.

Authors:  G D Lowe
Journal:  BMJ       Date:  1988-11-12

7.  Leukoaraiosis, intracerebral hemorrhage, and arterial hypertension.

Authors:  D Inzitari; G P Giordano; A L Ancona; G Pracucci; M Mascalchi; L Amaducci
Journal:  Stroke       Date:  1990-10       Impact factor: 7.914

8.  The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study.

Authors:  A R Wintzen; H de Jonge; E A Loeliger; G T Bots
Journal:  Ann Neurol       Date:  1984-11       Impact factor: 10.422

9.  [Spontaneous pontine hemorrhage. An analysis of 38 cases].

Authors:  H Bewermeyer; C Hojer; B Szelies; W F Haupt; M Neveling; W D Heiss
Journal:  Nervenarzt       Date:  1988-11       Impact factor: 1.214

10.  [Prognostic significance of initial clinical and instrumental parameters in spontaneous intracerebral hemorrhages].

Authors:  A Thie; K Spitzer; H Lappe; K Kunze
Journal:  Fortschr Neurol Psychiatr       Date:  1988-05       Impact factor: 0.752

View more
  14 in total

1.  Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies.

Authors:  Panagiotis N Papanikolaou; Georgia D Christidi; John P A Ioannidis
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

Review 2.  Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine.

Authors:  Jennifer A Frontera; John J Lewin; Alejandro A Rabinstein; Imo P Aisiku; Anne W Alexandrov; Aaron M Cook; Gregory J del Zoppo; Monisha A Kumar; Ellinor I B Peerschke; Michael F Stiefel; Jeanne S Teitelbaum; Katja E Wartenberg; Cindy L Zerfoss
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

Review 3.  A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place.

Authors:  Dawn Swan; David Julian Seiffge; Jecko Thachil
Journal:  J Neurol       Date:  2020-03-02       Impact factor: 4.849

4.  Oral anticoagulant treatment: risk factors involved in 500 intracranial hemorrhages.

Authors:  A Cantalapiedra; O Gutierrez; J I Tortosa; M Yañez; M Dueñas; E Fernandez Fontecha; M J Peñarrubia; L J García-Frade
Journal:  J Thromb Thrombolysis       Date:  2006-10       Impact factor: 2.300

5.  Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction.

Authors:  P F van Bergen; J W Deckers; J J Jonker; R T van Domburg; A J Azar; A Hofman
Journal:  Br Heart J       Date:  1995-08

6.  Warfarin use leads to larger intracerebral hematomas.

Authors:  M L Flaherty; H Tao; M Haverbusch; P Sekar; D Kleindorfer; B Kissela; P Khatri; B Stettler; O Adeoye; C J Moomaw; J P Broderick; D Woo
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

Review 7.  [Intracerebral hemorrhage related to anticoagulant therapy].

Authors:  H B Huttner; E Jüttler; A Hug; M Köhrmann; P D Schellinger; T Steiner
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

8.  Evaluation of Oral Anticoagulant-Associated Intracranial Parenchymal Hematomas Using CT Findings.

Authors:  E Gökçe; M Beyhan; B Acu
Journal:  Clin Neuroradiol       Date:  2014-01-29       Impact factor: 3.649

Review 9.  [Spontaneous intracerebral hemorrhages].

Authors:  A Hug; A Aschoff; S Schwab
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214

10.  Experimental model of warfarin-associated intracerebral hemorrhage.

Authors:  Christian Foerch; Ken Arai; Guang Jin; Kyung-Pil Park; Stefanie Pallast; Klaus van Leyen; Eng H Lo
Journal:  Stroke       Date:  2008-09-04       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.